Cytology News and Research

RSS

Cytology is the study of cells using a microscope.

Trovagene introduces urine-based HPV-HR DNA test for identifying high-risk HPV strains

Trovagene, Inc., today announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus test.

27 Mar 2013

Study to determine prevalence of abnormal anal cytology and HPV in at-risk women

A basic connection of statistics lead a researcher at Women & Infants Hospital of Rhode Island to question whether women should be screened for anal cancer during a regular visit to the gynecologist, and what technique is most effective.

18 Jan 2013

‘PapGene’ test detects endometrial and ovarian cancers

Researchers have adapted the papanicolaou smear test currently used to detect cervical cancer so that it can be used to screen women for endometrial and ovarian cancers.

14 Jan 2013

NCC to expand women's cancer programs in the developing world

The National Cancer Coalition (NCC) is expanding its efforts to fight women's cancers in the developing world.

14 Dec 2012

Roche’s cobas 4800 HPV Test receives CE mark

Roche today announces an expanded CE mark indication for the cobas 4800 HPV Test. The newly expanded indication for the cobas® 4800 HPV Test as a primary screen means Pap cytology is no longer required as a co- or pre-test in countries that accept a CE mark.

From Roche Sequencing and Life Science 27 Nov 2012

Leading urologic oncologist explains bladder cancer basics

An unhappy bladder won't be ignored. Frequent urination, pain while urinating, burning while urinating, blood in the urine, and even back pain or pelvic pain can all be symptoms of bladder cancer or other urinary tract problems. The trick, however, is that the absence of urinary symptoms doesn't guarantee a healthy bladder.

27 Nov 2012

HPV testing and cervical screening: an interview with Dr Rosa Legood

Human papillomavirus is a virus that is transmitted through sexual contact. In most cases the virus is transient and causes no harm, however in some cases it can go on to cause pre-cancer lesions and cervical cancer.

7 Nov 2012

Cervical cancer risk remains high after CIN treatment

Women who undergo treatment for screening-detected cervical intraepithelial neoplasia are more than four times more likely to develop cervical cancer than women with normal smear tests, research suggests.

5 Nov 2012

HPV test of cure cheaper and more effective than cytology testing for women following pre-cervical cancer treatment

Testing women to see if they are cured of HPV (the virus that can cause genital warts and cervical cancer) following treatment for abnormal cells on the surface of the cervix is more effective and cheaper than cytology testing (cervical screening) alone, suggests a study published on bmj.com.

2 Nov 2012

New diagnostic tool identifies metastatic ability of breast cancer cells

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and The Institute of Photonic Sciences (ICFO) have collaborated on the development of a diagnostic tool that identifies the metastatic ability of breast cancer cells.

20 Oct 2012

FDA approves Hologic’s APTIMA HPV 16 18/45 Genotype Assay for use on TIGRIS system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system.

From Hologic, Inc. 16 Oct 2012

Breast cancer… do you know who diagnoses you?

Australian women have a 1 in 9 lifetime risk of developing breast cancer and 1 in every 100 breast cancers occurs in men. In 2012, it is estimated that 14,610 women will be diagnosed with breast cancer, making it the most common cancer affecting women in Australia. However, despite this, few people realise that pathologists arguably play the most important role in the detection and treatment of breast cancer.

16 Oct 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

New York State Department of Health issues license to Veracyte's Afirma Gene Expression Classifier

Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, and Genzyme, a Sanofi company, today announced that the New York State Department of Health has issued a license enabling Veracyte's Afirma Gene Expression Classifier to be offered to patients in the state.

30 Aug 2012

HPV co-testing prospect for HIV-infected women

The risk for cervical precancer and cancer is similar in HIV-infected and HIV-uninfected women with normal cervical cytology and no evidence of oncogenic human papillomavirus infection, research shows.

30 Jul 2012

Study: HIV-infected women less likely to develop cervical cancer

HIV-infected and uninfected women with normal cervical cytology (Pap test) and a negative test result for oncogenic (tumor inducing) human papillomavirus DNA at study enrollment had a similar risk of cervical precancer and cancer after 5 years of follow-up, according to a study in the July 25 issue of JAMA, a theme issue on HIV/AIDS.

23 Jul 2012

CAP/ASCCP LAST Project recommendations for better diagnosis of HPV-associated lesions

The College of American Pathologists (CAP) and the American Society for Colposcopy and Cervical Pathology (ASCCP) jointly issued The Lower Anogenital Squamous Terminology (LAST) Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations.

4 Jul 2012

Afirma gene expression test can reduce unnecessary thyroid cancer surgeries

Veracyte, Inc., a molecular diagnostics company that is pioneering the emerging field of molecular cytology, today announced results from a large, prospective, multicenter study, which demonstrated the potential for the Afirma® Gene Expression Classifier, a gene expression test, to reduce the large number of unnecessary surgeries in thyroid cancer diagnosis by more than half.

25 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

New molecular test panel to enhance reliability of thyroid biopsy testing

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal.

From Quest Diagnostics 2 Jun 2012